Literature DB >> 497404

Comparison of fibrinogen association with normal and thrombasthenic platelets on exposure to ADP or chymotrypsin.

J F Mustard, R L Kinlough-Rathbone, M A Packham, D W Perry, E J Harfenist, K R Pai.   

Abstract

Although 125I-fibrinogen becomes associated with washed platelets from normal human subjects during ADP-induced shape change and aggregation, 125I-fibrinogen did not become associated with washed plateletes from a thrombasthenic subject during ADP-induced shape change and the platelets did not aggregate. Platelets from control and thrombasthenic subjects were treated with chymotrypsin, which is known to degrade platelet membrane glycoproteins. More 125I-fibrinogen became associated with chymotrypsin-pretreated platelets from normal subejcts than with untreated platelets, and fibrinogen caused the enzyme-treated platelets to aggregate. 125I-fibrinogen did not become associated with chymotrypsin-pretreated thromobasthenic platelets, and fibrinogen did not aggregate them. Thus, there appears to be a defect in thrombasthenic platelets that prevents the association of fibrinogen with them.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 497404

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  A new variant of Glanzmann's thrombasthenia (Strasbourg I). Platelets with functionally defective glycoprotein IIb-IIIa complexes and a glycoprotein IIIa 214Arg----214Trp mutation.

Authors:  F Lanza; A Stierlé; D Fournier; M Morales; G André; A T Nurden; J P Cazenave
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

2.  Divalent cation regulation of the surface orientation of platelet membrane glycoprotein IIb. Correlation with fibrinogen binding function and definition of a novel variant of Glanzmann's thrombasthenia.

Authors:  M H Ginsberg; A Lightsey; T J Kunicki; A Kaufmann; G Marguerie; E F Plow
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

3.  Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon.

Authors:  S R Hanson; F I Pareti; Z M Ruggeri; U M Marzec; T J Kunicki; R R Montgomery; T S Zimmerman; L A Harker
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

4.  Localization of internal pools of membrane glycoproteins involved in platelet adhesive responses.

Authors:  J D Wencel-Drake; E F Plow; T J Kunicki; V L Woods; D M Keller; M H Ginsberg
Journal:  Am J Pathol       Date:  1986-08       Impact factor: 4.307

5.  Identification of a new class of inducible receptors on platelets. Thrombospondin interacts with platelets via a GPIIb-IIIa-independent mechanism.

Authors:  M L Aiken; M H Ginsberg; E F Plow
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

6.  Binding of fibrinogen to human monocytes.

Authors:  D C Altieri; P M Mannucci; A M Capitanio
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

7.  Antiplatelet drugs and thrombosis prevention: ticlopidine in perspective.

Authors:  G de Gaetano; V Bertelé
Journal:  Agents Actions       Date:  1984-01

8.  A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa.

Authors:  B S Coller; E I Peerschke; L E Scudder; C A Sullivan
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

9.  Retention of the glycoprotein IIb-IIIa complex in the isolated platelet cytoskeleton. Effects of separable assembly of platelet pseudopodal and contractile cytoskeletons.

Authors:  M E Wheeler; A C Cox; R C Carroll
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

10.  A variant of Glanzmann's thrombasthenia with abnormal glycoprotein IIb-IIIa complexes in the platelet membrane.

Authors:  A T Nurden; J P Rosa; D Fournier; C Legrand; D Didry; A Parquet; D Pidard
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.